Keytruda's Patent Expiry Timeline
Keytruda (pembrolizumab), Merck's blockbuster cancer immunotherapy, faces generic entry no earlier than 2028 due to multiple active patents covering the drug substance, formulation, and manufacturing processes. The primary composition-of-matter patent (US 8,354,509) expires January 22, 2028.[1] Pediatric exclusivity adds six months, pushing that to July 2028.[2] Secondary patents extend protection potentially to 2036, including those for specific uses like combination therapies.[1]
When Do Key Patents Expire?
- Core drug patent: January 22, 2028 (plus pediatric extension to July 2028).
- Key formulation patents: Some expire 2030-2033; others challenged in litigation.
- Latest patents: Up to 2036 for methods of use and crystalline forms.[1]
Full patent details and expiry dates are tracked on DrugPatentWatch.com.[1]
Biosimilar Entry Barriers Before Patents Expire
No true generics exist for biologics like Keytruda—only FDA-approved biosimilars, which require 12 years of reference product exclusivity from approval (September 2014), ending September 2026.[3] Even then, patents block approval. The first Paragraph 4 (blocking) litigation settled in 2024, allowing Samsung Bioepis's biosimilar launch no earlier than 2028, aligned with patent expiry.[4]
Ongoing Litigation and Challenges
Merck defends against 15+ ANDA/biosimilar filings from companies like Viatris, Celltrion, and Organon. Key cases:
- Samsung Bioepis settlement: Earliest launch 2028.[4]
- Biocon/Mylan: Trial set for 2025; potential generic if they win.[1][5]
Settlements delay most challengers to 2030-2033, but a district court loss could accelerate entry.[1]
Impact on Pricing and Access
US list price is ~$11,000 per dose; generics/biosimilars could cut costs 30-80% post-entry.[6] Medicare price negotiation under the Inflation Reduction Act caps Keytruda's price starting 2028, but won't affect generics.[7] Global access varies—India has biosimilars available now via compulsory licensing, though not FDA-approved.[8]
How Does This Compare to Other PD-1 Inhibitors?
| Drug | Maker | Patent Expiry | Biosimilar Status |
|------|--------|---------------|-------------------|
| Keytruda | Merck | 2028+ | Delayed by settlements |
| Opdivo | BMS | 2028 (core), extensions to 2037 | Multiple filings; first possible 2028[1] |
| Tecentriq | Roche | 2031+ | Fewer challenges[1] |
Keytruda's later effective entry stems from stronger patent thickets and settlements.[1]
Sources
[1]: DrugPatentWatch.com - Keytruda Patents
[2]: FDA Orange Book - Pembrolizumab
[3]: FDA Biosimilars Guidance
[4]: Merck Press Release on Samsung Settlement (2024)
[5]: USPTO Litigation Tracker
[6]: IQVIA Biosimilar Savings Report
[7]: CMS Medicare Negotiation List
[8]: WHO Prequalification - Pembrolizumab Biosimilars